Similarly, tivozanib is an inhibitor of VEGFR1, VEGFR2, VEGFR3, and PDGFRβ, approved by the U.S. FDA in 2021 for the third-line therapy for advanced RCC (132–134). The gene discussed is FLT4; the disease is renal cell carcinoma.